Tim Davie became Director-General of the BBC on 1 September 2020. He is the 17th Director-General of the Corporation. Prior to this, Tim was Chief Executive of BBC Studios, the BBC’s principal ...
GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3, after its cobolimab candidate flunked a phase 3 trial in lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback